MetaCap

Zentalis Pharmaceuticals Inc. (ZNTL)

NASDAQ: ZNTLHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.360.00 (0.00%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ZNTL stock chart

Technical analysis

Key statistics

All statistics
Market cap
$133.64M
EPS (TTM)
-$1.90
52-week range
1.30 – 6.95
Day range
1.33 – 1.50
Volume / Avg
1.46M / 1.26M
Beta
—

52-week range

$1.30$6.95

ZNTL stock today

Zentalis Pharmaceuticals (ZNTL) closed at $1.36 on Nov 20, essentially unchanged from the prior close, versus the S&P 500's 3.70% decline. At this level, ZNTL sits near the bottom of its 52-week range of $1.30 to $6.95: 80.4% below the high, set on Apr 10, 2026 and 4.6% above the low. ZNTL is up 0.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 1.5%.

Zentalis Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$1.90), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Zentalis Pharmaceuticals

Company profile

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Ms. Julie M. Eastland M.B.A.
Headquarters
San Diego, CA
Employees
106
IPO year
2020

Financial highlights

Full financials

In fiscal 2025, Zentalis Pharmaceuticals generated $0 in revenue, down 100.0% from fiscal 2024, the first decline in the 7 years shown. Zentalis Pharmaceuticals reported a net loss of $137.1 million, compared with a loss of $165.8 million a year earlier. Diluted earnings per share came in at -$1.91.

Zentalis Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$0$67.42M$0$0—
Growth-100.00%————
Net income$-137.06M$-165.84M$-292.19M$-236.81M$-158.72M
EPS (diluted)$-1.91$-2.33$-4.47$-4.48$-3.72

Analyst forecast

Forecast

Consensus (11 analysts)

strong_buy

Avg. price target

$7.44+447.06%

  • Strong buy 0
  • Buy 9
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $5.00High $10.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.34 vs $-0.58
Surprise
+41.38%

ZNTL news

All ZNTL news

Zentalis Pharmaceuticals peers

Health Care sector
ZNTL peer companies
CompanyPrice% ChgMarket capCompare
ALXOALX Oncology Holdings Inc.1.06+3.92%$137.03Mvs ZNTL
SIONSionna Therapeutics Inc.2.83-4.88%$127.79Mvs ZNTL
MGNXMacroGenics Inc.1.96-1.01%$125.26Mvs ZNTL
BBOTBridgeBio Oncology Therapeutics Inc.1.81-2.69%$145.25Mvs ZNTL
MSLESatellos Bioscience Inc.5.68-2.07%$120.51Mvs ZNTL
PRQRProQR Therapeutics N.V.1.04-0.95%$146.98Mvs ZNTL
VRXAVeraxa Biotech AG1.04+0.97%$147.06Mvs ZNTL
ADAGAdagene Inc. ADR1.76-12.44%$118.17Mvs ZNTL

Indexes, lists and sector

Zentalis Pharmaceuticals stock FAQ

What is Zentalis Pharmaceuticals's stock price today?

ZNTL last traded at $1.36 as of Nov 20, 4:00 PM EST, up 0.00% on the day. Prices are delayed at least 15 minutes.

Who is Zentalis Pharmaceuticals's CEO?

Ms. Julie M. Eastland M.B.A. is the chief executive officer of Zentalis Pharmaceuticals Inc., which has about 106 employees.

What is the ZNTL 52-week high?

The 52-week high for ZNTL is $6.95 and the 52-week low is $1.30. The stock is currently 80.4% below its high.

Compare ZNTL